Investing in European Health R&D

A report published on 7 October shows that European research and development investments in health have stagnated since 2010, and this is the first time after decades of annual increases. The report was commissioned by Janssen Pharmaceutica NV and the research was conducted by Deloitte Health Economics group. According to the report, this decline is due to the current economic situation, reinforced by the uncertainty about future market conditions, and increasingly limited reward mechanisms for innovative technologies, amongst others. Read the full article.